iCAD (ICAD) Projected to Post Quarterly Earnings on Tuesday

iCAD (NASDAQ:ICAD) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect iCAD to post earnings of ($0.06) per share and revenue of $4.54 million for the quarter.

iCAD (NASDAQ:ICAD) last announced its earnings results on Wednesday, March 19th. The technology company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. The business had revenue of $5.41 million for the quarter, compared to analyst estimates of $4.72 million. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%.

iCAD Stock Down 0.6 %

Shares of iCAD stock opened at $3.46 on Tuesday. The business has a 50-day moving average price of $2.42 and a 200 day moving average price of $2.27. iCAD has a fifty-two week low of $1.18 and a fifty-two week high of $3.78. The firm has a market cap of $94.91 million, a P/E ratio of -26.60 and a beta of 1.35.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Laidlaw reaffirmed a “hold” rating on shares of iCAD in a report on Thursday, April 17th. Craig Hallum lowered iCAD from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 16th. StockNews.com started coverage on iCAD in a research report on Sunday. They set a “sell” rating on the stock. Finally, BTIG Research downgraded shares of iCAD from a “buy” rating to a “neutral” rating in a research report on Wednesday, April 16th.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.